30235-12-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Cyano-6-methyl-4-nitropyridine is used as a key intermediate in the synthesis of hydrochloride of 2-methyl-4-pyrrolidinyl-6-[(E)-2-(3-trifluoromethylphenyl)vinyl]pyridine, a selective Y5 receptor antagonist. This antagonist has potential applications in the treatment of various disorders related to the neuropeptide Y system, such as obesity, anxiety, and depression.
Additionally, 2-Cyano-6-methyl-4-nitropyridine can be utilized in the development of other pharmaceutical compounds with diverse therapeutic applications, owing to its versatile chemical structure and reactivity. Its presence in the synthesis process allows for the creation of new molecules with potential medicinal properties, making it a valuable component in the field of drug discovery and development.

InChI:InChI=1/C7H5N3O2/c1-5-2-7(10(11)12)3-6(4-8)9-5/h2-3H,1H3

Upstream product

• 5470-66-6 2-methyl-4-nitropyridine N-oxide 
• 151-50-8 potassium cyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 235742-74-2 2-cyano-3-methoxy-6-methylpyridine 
• 30235-19-9 4-chloro-6-methylpyridine-2-carboxylic acid 

Relevant academic research and scientific papers

OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING

The invention is directed to Compounds of Formula (I): wherein each variable is defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance for treating graft versus host disease and autoimmune diseases.

THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING

The invention is directed to compounds of the formula: wherein each of the variables are defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance treating an autoimmune disease.

1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO

Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

N-(phenylsulfonyl)picolinamide derivatives, process for producing the same, and herbicide

A herbicide containing as the active ingredient an N-(henylsulfonyl)picolinamide derivative represented by general formula (I) wherein X reprcsents a halogeno, a C1-4 alkyl, a C1-4 haloalkyl, a C1-4 alkoxy, a C1-4 haloalkoxy, a (C1-4 alkoxy)carbonyl, a [di(C1-4 alkyl)amino]sulfonyl, an [N—(C1-4 alkyl)-N—(C1-4 alkoxy)amino]sulfonyl, a (C1-4 alkylamino)sulfonyl, a C1-4 alkylthio, a C1-4 alkylsulfinyl, a C1-4 alkylsulfonyl, or nitro; n is an integer of 0 to 5; Y represets a halogeno, a C1-4 alkyl, a C1-4 haloalkyl, a C1-4 alkoxy, C1-4 haloalkoxy, a C1-4 alkylthio, a C1-4 haloalkylthio, amino, a C1-4 alkylamino, a di(C1-4 alkyl)amino, a (C1-4 alkoxy) C1-4 alkyl, a (C1-4 alkylthio) C1-4 alkyl, or nitro; and m is an integer of 0 to 4. This active ingredient is synthesized by condensing a substituted picolinic acid with a substituted benzenesulfonamide under dehydration, or by reacting the phenyl ester of a substituted picolinic acid with a substituted benzenesulfonamide in the presence of a basic compound.

Efficient synthesis of a selective Y5 receptor antagonist

A selective Y5 receptor antagonist, the hydrochloride of 2-methyl-4-pyrrolidinyl-6-[(E)-2-(3-trifluoromethylphenyl)-vinyl]pyridine, can be prepared in a 7-step synthesis.

Carbonylation of hydrocarbylpalladium(II) complexes containing substituted pyridinecarboxylate chelating ligands. Steric and electronic manipulation of the CO-insertion mechanism

Organopalladium(II) complexes of general formula [PdR(N-O)L] [R = Ph, N-O = pyridinecarboxylate (pyca), L = P(C6H11)3; R = Ph, N-O = 6-methylpyridinecarboxylate (mpyca), L = PPh3, PMePh2, P(C6H11)3 or PEt3; R = Ph, N-O = 4-nitropyridinecarboxylate (npyca), L = P(C6H11)3; R = Ph, N-O = 6-methyl-4-nitropyridinecarboxylate, L = P(C6H11)3; R = Me, N-O = mpyca, L = PPh3, P(CH2Ph)3 or P(C6H11)3; R = Me, N-O = npyca, L = PPh3, PMePh2 or P(C6H11)3] have been prepared, and their carbonylation reactions studied in detail. Kinetic studies of the CO-insertion process have indicated that the rate of reaction decreases as the basicity of the phosphine, L, increases. Complexes containing the highly basic phosphine P(C6H11)3 only undergo carbonylation if hemilability of the chelating ligand is promoted (by substitution of the N-O chelate). Substitution of the N-O ligand modifies the carbonylation pathway and provides an alternative route from that generally observed for palladium(II) and platinum(II) hydrocarbyl complexes of pyca. A mechanism for insertion of CO involving partial dissociation of the N-O chelate is proposed for these complexes. The crystal stucture of [PdMe(mpyca)(PPh3)] has been determined. The complex has square-planar co-ordination with the nitrogen of pyca trans to the phosphorus. Considerable distortion of the inner co-ordination sphere is evident, caused by steric interactions betwen the σ-methyl ligand and the methyl group on the N-O ligand.